Dinoprostone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dinoprostone: From Pregnancy Disorder with Abortive Outcome to Esotropia
One-Sentence Summary
Dinoprostone is a prostaglandin E2 (PGE2) medicine, originally used in obstetrics for pregnancy disorders with abortive outcome and gestational trophoblastic neoplasm. The TxGNN model predicts it may be effective for esotropia, but no clinical trials and no publications currently support this prediction, so it is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pregnancy disorder with abortive outcome; gestational trophoblastic neoplasm (from the knowledge graph; the Singapore licence records carry no indication text) |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 98.26% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the data compiled for this report. Based on known pharmacology, dinoprostone is a prostaglandin E2 analog that acts on EP receptors, causing smooth muscle contraction and cervical ripening. This explains its obstetric use.
No plausible mechanistic link to esotropia, an ocular motor alignment disorder, is evident. The high score (0.983) most likely reflects network-level patterns in the knowledge graph rather than a biological rationale. The prediction should be treated as a hypothesis only, and it is not supported by any clinical or mechanistic data.
Other lower-ranked predictions show the same pattern. These include atypical coarctation of the aorta, aortic malformation, acne, immunodeficiencies, HER2-positive breast carcinoma, pyelonephritis, drug-induced osteoporosis and cervical neuroblastoma. All are at evidence level L5 with no trials or literature. Two deserve a specific note:
- HER2-positive breast carcinoma: PGE2/COX-2 signaling is linked to tumour progression, so the direction of effect may be harmful.
- Drug-induced osteoporosis: PGE2 has preclinical anabolic bone effects, which is the only biologically plausible hypothesis, but it would need preclinical validation first.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13982P | Cervidil Vaginal Delivery System 10mg | Other (vaginal delivery system) | Not stated in the registration data |
| SIN02520P | PROSTIN E2 VAGINAL TABLET 3 mg | Tablet | Not stated in the registration data |
Safety Considerations
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for safety information.
The knowledge graph lists the following conditions as contraindication-related for dinoprostone. These come from graph relationships, not from label text, and should be verified against the official label:
- Cardiovascular and blood pressure: hypertension, hypotensive disorder, cardiovascular disease, heart disease
- Respiratory: asthma (intrinsic and allergic), lung disease
- Metabolic: diabetes mellitus, diabetic ketoacidosis
- Organ disease: kidney disease, liver disease, gallbladder disease
- Neurological and eye: epilepsy, glaucoma, ocular hypertension
- Blood: anaemia, disseminated intravascular coagulation, purpura fulminans
- Gynaecological and infectious: uterine leiomyoma, cervicitis, genital herpes, pyoureter
No drug-interaction data were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for esotropia rests on a model score alone, with no clinical trials, no literature and no plausible mechanism. Dinoprostone is a locally administered obstetric product, and the evidence does not justify advancing the repurposing candidate.
To proceed, the following is needed:
- Mechanism of action data (DrugBank), and an assessment of whether any biological link to esotropia exists
- Package insert warnings and contraindications from the HSA, which are needed before any safety screening
- A literature and trial search specific to dinoprostone/PGE2 and esotropia
- Route and formulation compatibility analysis, since current products are vaginal or oral
- Preclinical evidence, if the team wants to pursue a better-grounded alternative such as drug-induced osteoporosis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.